255 related articles for article (PubMed ID: 2466045)
1. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
[TBL] [Abstract][Full Text] [Related]
2. Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush.
Balks HJ; Conlon JM; Creutzfeldt W; Stöckmann F
Eur J Clin Pharmacol; 1989; 36(2):133-7. PubMed ID: 2470592
[TBL] [Abstract][Full Text] [Related]
3. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush.
Norheim I; Theodorsson-Norheim E; Brodin E; Oberg K
J Clin Endocrinol Metab; 1986 Sep; 63(3):605-12. PubMed ID: 2426299
[TBL] [Abstract][Full Text] [Related]
4. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
5. Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog.
Vinik AI; Gonin J; England BG; Jackson T; McLeod MK; Cho K
J Clin Endocrinol Metab; 1990 Jun; 70(6):1702-9. PubMed ID: 1693375
[TBL] [Abstract][Full Text] [Related]
6. SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization.
Ahlman H; Ahlund L; Dahlström A; Martner J; Stenqvist O; Tylén U
Anesth Analg; 1988 Dec; 67(12):1142-8. PubMed ID: 2461665
[TBL] [Abstract][Full Text] [Related]
7. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
8. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
9. Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites.
Matuchansky C; Launay JM
Gastroenterology; 1995 Mar; 108(3):743-51. PubMed ID: 7533112
[TBL] [Abstract][Full Text] [Related]
10. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of carcinoid syndrome with a somatostatin analogue].
Döbrönte Z; Stöckert A; Végh G; Varga L
Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
[TBL] [Abstract][Full Text] [Related]
12. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival.
Norheim I; Oberg K; Theodorsson-Norheim E; Lindgren PG; Lundqvist G; Magnusson A; Wide L; Wilander E
Ann Surg; 1987 Aug; 206(2):115-25. PubMed ID: 2440390
[TBL] [Abstract][Full Text] [Related]
13. Distinguishing features of idiopathic flushing and carcinoid syndrome.
Aldrich LB; Moattari AR; Vinik AI
Arch Intern Med; 1988 Dec; 148(12):2614-8. PubMed ID: 2461688
[TBL] [Abstract][Full Text] [Related]
14. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor].
Goñi F; Oleaga A; Goñi MJ; Monreal M; Yoldi A; González A; Llorente I; Moncada E
Rev Clin Esp; 1991 Nov; 189(7):331-4. PubMed ID: 1722585
[TBL] [Abstract][Full Text] [Related]
15. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
16. [A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
Del Val A; Ponce J; Talens A; Martí-Bonmati L; Garrigues V; Berenguer J
Rev Esp Enferm Dig; 1991 Mar; 79(3):215-7. PubMed ID: 2043408
[TBL] [Abstract][Full Text] [Related]
17. Octreotide treatment of carcinoid hypertensive crisis.
Warner RR; Mani S; Profeta J; Grunstein E
Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
[TBL] [Abstract][Full Text] [Related]
18. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
[TBL] [Abstract][Full Text] [Related]
19. The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin.
Ahlman H; Dahlström A; Grönstad K; Tisell LE; Oberg K; Zinner MJ; Jaffe BM
Ann Surg; 1985 Jan; 201(1):81-6. PubMed ID: 2578277
[TBL] [Abstract][Full Text] [Related]
20. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
